Its a promising announcement, but it also raises the inevitable question of funding.
First clinical trials of PAT-DX1 in H2 CY2023 in cancer patients is great news from a development/clinical perspective, from an investment perspective is raises the obvious question of how much $$ do we have in the bank.
Couple that with a market that has a very ''risk off'' attitude and I imagine will do for some time yet, this one is still a long, long term proposition.
Thats why all this ''10c by Christmas'' hyperbole irritates me, it turns otherwise good posts into dribble.
Its a promising announcement, but it also raises the inevitable...
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $19.49K | 2.78M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1514113 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1874624 | 9 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |